This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global demand is lifting healthcare

By Robert Freedland

In May and into early June, 2014, the Healthcare Sector portfolio has improved its performance and I continue to look for the strongest stocks in the sector to buy.

I reduced my cash position, which I had raised when biotech stocks tumbled earlier this year. I also started a new position in Anika (ANIK), a company that makes a wide variety of hyaluronic acid products for diverse uses from ophthalmic applications to orthopedic and dermatologic uses.

Anika has been a very volatile holding for me and hopefully this will move solidly into the profit column in the future giving me some additional leeway with this position.

I remain committed to cutting losses as they develop very early in the process and have parted with some positions prematurely when examined with 20/20 hindsight.

One of the stocks that I have brought back to Healthcare portfolio after selling is Biogen Idec (BIIB). Biogen is a leading pharmaceutical company with products that serve the market for more than 2 million patients worldwide fighting Multiple Sclerosis (MS).

As I have written before, I believe that the growing consensus to bring uninsured people into the healthcare system is driving demand for medical products and services for the industry.

Coupled with an aging population worldwide, where middle classes in China, India and elsewhere seek better lives, the demand for medications, medical devices and pharmaceuticals and medical services will increase in my opinion.

Healthcare stocks will remain volatile, but I shall try to hold on to the companies that continue to grow their businesses and try to replace those that falter with other new names.

DISCLAIMER: The investments discussed are held in client accounts as of May 31, 2013. These investments may or may not be currently held in client accounts. The reader should not assume that any investments identified were or will be profitable or that any investment recommendations or investment decisions we make in the future will be profitable. Past performance is no guarantee of future results.

Robert Freedland

Robert Freedland

Robert has over 40 years of investment experience and is a full-time optical surgeon. He uses his expertise in the

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,079.91 +41.94 0.23%
S&P 500 2,112.89 +3.97 0.19%
NASDAQ 5,064.0280 +3.7820 0.07%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs